The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies
Open accessAbstract
BACKGROUND AND OBJECTIVES: Complicated vascular anomalies have limited therapeutic options and cause significant morbidity and mortality. This Phase II trial enrolled patients with complicated vascular anomalies to determine the efficacy and safety of treatment with sirolimus for 12 courses; each course was defined as 28 days. METHODS: Treatment consisted of a continuous dosing schedule of oral sirolimus starting at 0.8 mg/m2 per dose twice daily, with pharmacokinetic-guided target serum trough levels of 10 to 15 ng/mL. The primary outcomes were responsiveness to sirolimus by the end of course 6 (evaluated according to functional impairment score, quality of life, and radiologic assessment) and the incidence of toxicities and/or infection-related deaths. RESULTS: Sixty-one patients were enrolled; 57 patients were evaluable for efficacy at the end of course 6, and 53 were evaluable at the end of course 12. No patient had a complete response at the end of course 6 or 12 as anticipated. At the end of course 6, a total of 47 patients had a partial response, 3 patients had stable disease, and 7 patients had progressive disease. Two patients were taken off of study medicine secondary to persistent adverse effects. Grade 3 and higher toxicities attributable to sirolimus included blood/bone marrow toxicity in 27% of patients, gastrointestinal toxicity in 3%, and metabolic/laboratory toxicity in 3%. No toxicity-related deaths occurred. CONCLUSIONS: Sirolimus was efficacious and well tolerated in these study patients with complicated vascular anomalies. Clinical activity was reported in the majority of the disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Hemangiomas and Vascular Malformations in Infants and Children
Mulliken, J. B., & Glowacki, J. (1982) · Plastic & Reconstructive Surgery · doi:10.1097/00006534-198203000-00002 · Cited by 3,322
Wassef, M., Blei, F., Adams, D., Alomari, A., Baselga, E., Berenstein, A., Burrows, P., Frieden, I. J., Garzon, M. C., Lopez-Gutierrez, J.-C., et al. (2015) · Pediatrics · doi:10.1542/peds.2014-3673 · Cited by 1,419
Self-citationSirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
Efficacy and safety of sirolimus in lymphangioleiomyomatosis
McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100391 · Cited by 1,099
mTOR-targeted therapy of cancer with rapamycin derivatives
Vignot, S., Faivre, S., Aguirre, D., & Raymond, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 617
Somatic Mosaic Activating Mutations in PIK3CA Cause CLOVES Syndrome
Kurek, K. C., Luks, V. L., Ayturk, U. M., Alomari, A. I., Fishman, S. J., Spencer, S. A., Mulliken, J. B., Bowen, M. E., Yamamoto, G. L., Kozakewich, H. P. W., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.05.006 · Cited by 532
Revencu, N., Boon, L. M., Mulliken, J. B., Enjolras, O., Cordisco, M. R., Burrows, P. E., Clapuyt, P., Hammer, F., Dubois, J., Baselga, E., et al. (2008) · Human Mutation · doi:10.1002/humu.20746 · Cited by 435
PI3K/PTEN signaling in tumorigenesis and angiogenesis
Jiang, B.-H., & Liu, L.-Z. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.09.008 · Cited by 345
mTOR, translational control and human disease
Tee, A. R., & Blenis, J. (2005) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2004.11.005 · Cited by 320
Zhou, X.-P., Hampel, H., Thiele, H., Gorlin, R. J., Hennekam, R. C., Parisi, M., Winter, R. M., & Eng, C. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05412-5 · Cited by 225
Osborn, A. J., Dickie, P., Neilson, D. E., Glaser, K., Lynch, K. A., Gupta, A., & Dickie, B. H. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu505 · Cited by 166
Self-citationVenous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB
Uebelhoer, M., Nätynki, M., Kangas, J., Mendola, A., Nguyen, H., Soblet, J., Godfraind, C., Boon, L. M., Eklund, L., Limaye, N., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt198 · Cited by 140
All Roads Lead to mTOR: Integrating Inflammation and Tumor Angiogenesis
Lee, D.-F., & Hung, M.-C. (2007) · Cell Cycle · doi:10.4161/cc.6.24.5085 · Cited by 115
Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology
Fogel, A. L., Hill, S., & Teng, J. M. C. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.01.014 · Cited by 66
Perry, B. N., Banyard, J., McLaughlin, E. R., Watnick, R., Sohn, A. M., Brindley, D. N., Obata, T., Cantley, L. C., Cohen, C., & Arbiser, J. L. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.4.504 · Cited by 63
Morris, P. N., Dunmore, B. J., Tadros, A., Marchuk, D. A., Darland, D. C., D'Amore, P. A., & Brindle, N. P. J. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0601-9 · Cited by 55
The Role of the Hematologist/Oncologist in the Care of Patients with Vascular Anomalies
Adams, D. M., & Wentzel, M. S. (2008) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2008.01.007 · Cited by 42
Self-citation
Cited by
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“In patients with vascular anomalies associated with elevated PI3K/AKT/mTOR signaling, rapamycin produced partial responses in 47 of 57 patients enrolled in a phase 2 study (Adams et al., 2016) (Table 1).”
PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism
Ren, A. A., Snellings, D. A., Su, Y. S., Hong, C. C., Castro, M., Tang, A. T., Detter, M. R., Hobson, N., Girard, R., Romanos, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03562-8 · Cited by 201
The Role of Rapamycin in Healthspan Extension via the Delay of Organ Aging
Zhang, Y., Zhang, J., & Wang, S. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101376 · Cited by 92
Metadata
- Authors
- Adams, D. M., Trenor, C. C., Hammill, A. M., Vinks, A. A., Patel, M. N., Chaudry, G., Wentzel, M. S., Mobberley-Schuman, P. S., Campbell, L. M., Brookbank, C., Gupta, A., Chute, C., Eile, J., McKenna, J., Merrow, A. C., Fei, L., Hornung, L., Seid, M., Dasgupta, A. R., Dickie, B. H., Elluru, R. G., Lucky, A. W., Weiss, B., & Azizkhan, R. G.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2016-02-01
- Volume
- 137
- Issue
- 2
- Pages
- e20153257-e20153257
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2392938395
- Cited by
- 844
- References
- 18
- FWCI
- 74.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.